Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome

Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome

ObjectiveRheumatic disease-associated macrophage activation syndrome (RD-MAS) is a rare and life-threatening complication of rheumatic diseases, with approximately 30% of cases being refractory to conventional therapeutic protocols. Ruxolitinib, a Janus kinase 1/2 inhibitor, has emerged as a potenti...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingjing Li, Ran Wang, Jie Chen, Antao Xu, Yakai Fu, Yanwei Lin, Xiaodong Wang, Shuang Ye, Ye Yuan, Fang Du, Qiong Fu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
refractory macrophage activation syndrome (MAS)
rheumatic diseases
ruxolitinib
JAK inhibitor
salvage treatment
real-world evidence
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1604648/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1604648/full

Similar Items